Clofazimine enteropathy in a pediatric bone marrow transplant recipient

M Parizhskaya; N N Youssef; C Di Lorenzo; R K Goyal

doi:10.1067/mpd.2001.111327

Clofazimine enteropathy in a pediatric bone marrow transplant recipient

J Pediatr. 2001 Apr;138(4):574-6. doi: 10.1067/mpd.2001.111327.

Authors

M Parizhskaya¹, N N Youssef, C Di Lorenzo, R K Goyal

Affiliation

¹ Department of Pathology, Division of Gastroenterology, Children's Hospital of Pittsburgh and the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15513, USA.

PMID: 11295724
DOI: 10.1067/mpd.2001.111327

Abstract

Clofazimine, previously used in the treatment of leprosy, is now used for treatment of Mycobacterium avium complex infection in patients with acquired immune deficiency syndrome, dermatologic disorders, and graft-versus-host disease. An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease. Clofazimine enteropathy caused by crystal deposition can be life-threatening.

Publication types

Case Reports

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
Biopsy
Bone Marrow Transplantation / immunology*
Child
Clofazimine / adverse effects*
Duodenal Diseases / chemically induced*
Duodenal Diseases / pathology
Duodenum / pathology
Endoscopy, Gastrointestinal
Graft vs Host Disease / drug therapy*
Graft vs Host Disease / etiology
Humans
Ileal Diseases / chemically induced*
Ileal Diseases / pathology
Male

Substances

Anti-Inflammatory Agents, Non-Steroidal
Clofazimine